CRABP1 and hepatocellular carcinoma: Previous research has indicated that MAP, a tetracyclic antidepressant, exerts its therapeutic effects by blocking the reuptake of norepinephrine by presynaptic membranes to alleviate mental retardation, achieve an antidepressant effect,[84] and exhibit visual protection properties.[85] Furthermore, many studies have demonstrated that MAP suppresses the development of hepatocellular carcinoma by targeting CRABP1 to inhibit cholesterol biosynthesis.[86]